372 related articles for article (PubMed ID: 27103349)
1. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF.
Mercer PF; Woodcock HV; Eley JD; Platé M; Sulikowski MG; Durrenberger PF; Franklin L; Nanthakumar CB; Man Y; Genovese F; McAnulty RJ; Yang S; Maher TM; Nicholson AG; Blanchard AD; Marshall RP; Lukey PT; Chambers RC
Thorax; 2016 Aug; 71(8):701-11. PubMed ID: 27103349
[TBL] [Abstract][Full Text] [Related]
2. A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis.
Lukey PT; Harrison SA; Yang S; Man Y; Holman BF; Rashidnasab A; Azzopardi G; Grayer M; Simpson JK; Bareille P; Paul L; Woodcock HV; Toshner R; Saunders P; Molyneaux PL; Thielemans K; Wilson FJ; Mercer PF; Chambers RC; Groves AM; Fahy WA; Marshall RP; Maher TM
Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30765508
[TBL] [Abstract][Full Text] [Related]
3. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W
Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
5. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
McKinnon T; Venier R; Yohe M; Sindiri S; Gryder BE; Shern JF; Kabaroff L; Dickson B; Schleicher K; Chouinard-Pelletier G; Menezes S; Gupta A; Zhang X; Guha R; Ferrer M; Thomas CJ; Wei Y; Davani D; Guidos CJ; Khan J; Gladdy RA
Oncogene; 2018 May; 37(20):2630-2644. PubMed ID: 29487419
[TBL] [Abstract][Full Text] [Related]
6. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
Grilley-Olson JE; Bedard PL; Fasolo A; Cornfeld M; Cartee L; Razak AR; Stayner LA; Wu Y; Greenwood R; Singh R; Lee CB; Bendell J; Burris HA; Del Conte G; Sessa C; Infante JR
Invest New Drugs; 2016 Dec; 34(6):740-749. PubMed ID: 27450049
[TBL] [Abstract][Full Text] [Related]
7. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.
Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA
PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477
[TBL] [Abstract][Full Text] [Related]
8. Targeted inhibition of PI3 kinase/mTOR specifically in fibrotic lung fibroblasts suppresses pulmonary fibrosis in experimental models.
Hettiarachchi SU; Li YH; Roy J; Zhang F; Puchulu-Campanella E; Lindeman SD; Srinivasarao M; Tsoyi K; Liang X; Ayaub EA; Nickerson-Nutter C; Rosas IO; Low PS
Sci Transl Med; 2020 Oct; 12(567):. PubMed ID: 33115948
[TBL] [Abstract][Full Text] [Related]
9. The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis.
Lawrence J; Nho R
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29518028
[TBL] [Abstract][Full Text] [Related]
10. Duvelisib attenuates bleomycin-induced pulmonary fibrosis via inhibiting the PI3K/Akt/mTOR signalling pathway.
Li X; Ma X; Miao Y; Zhang J; Xi B; Li W; Zhang Q; Chen L; Yang Y; Li H; Wei L; Zhou H; Yang C
J Cell Mol Med; 2023 Feb; 27(3):422-434. PubMed ID: 36651446
[TBL] [Abstract][Full Text] [Related]
11. Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases.
Vaidhyanathan S; Wilken-Resman B; Ma DJ; Parrish KE; Mittapalli RK; Carlson BL; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2016 Feb; 356(2):251-9. PubMed ID: 26604245
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
Leung E; Kim JE; Rewcastle GW; Finlay GJ; Baguley BC
Cancer Biol Ther; 2011 Jun; 11(11):938-46. PubMed ID: 21464613
[TBL] [Abstract][Full Text] [Related]
13. Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors.
Álvarez RM; García AB; Riesco-Fagundo C; Martín JI; Varela C; Rodríguez Hergueta A; González Cantalapiedra E; Oyarzabal J; Di Geronimo B; Lorenzo M; Albarrán MI; Cebriá A; Cebrián D; Martínez-González S; Blanco-Aparicio C; Pastor J
Eur J Med Chem; 2021 Feb; 211():113109. PubMed ID: 33360802
[TBL] [Abstract][Full Text] [Related]
14. [11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers.
Wang M; Gao M; Miller KD; Sledge GW; Zheng QH
Bioorg Med Chem Lett; 2012 Feb; 22(4):1569-74. PubMed ID: 22297110
[TBL] [Abstract][Full Text] [Related]
15. CCN5 overexpression inhibits profibrotic phenotypes via the PI3K/Akt signaling pathway in lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and in an in vivo model of lung fibrosis.
Zhang L; Li Y; Liang C; Yang W
Int J Mol Med; 2014 Feb; 33(2):478-86. PubMed ID: 24276150
[TBL] [Abstract][Full Text] [Related]
16. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
17. Niclosamide Ethanolamine Salt Alleviates Idiopathic Pulmonary Fibrosis by Modulating the PI3K-mTORC1 Pathway.
Pei X; Zheng F; Li Y; Lin Z; Han X; Feng Y; Tian Z; Ren D; Cao K; Li C
Cells; 2022 Jan; 11(3):. PubMed ID: 35159160
[TBL] [Abstract][Full Text] [Related]
18. The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis.
Woodcock HV; Eley JD; Guillotin D; Platé M; Nanthakumar CB; Martufi M; Peace S; Joberty G; Poeckel D; Good RB; Taylor AR; Zinn N; Redding M; Forty EJ; Hynds RE; Swanton C; Karsdal M; Maher TM; Fisher A; Bergamini G; Marshall RP; Blanchard AD; Mercer PF; Chambers RC
Nat Commun; 2019 Jan; 10(1):6. PubMed ID: 30602778
[TBL] [Abstract][Full Text] [Related]
19. Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis.
Xia H; Diebold D; Nho R; Perlman D; Kleidon J; Kahm J; Avdulov S; Peterson M; Nerva J; Bitterman P; Henke C
J Exp Med; 2008 Jul; 205(7):1659-72. PubMed ID: 18541712
[TBL] [Abstract][Full Text] [Related]
20. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
